CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Left Sided Metastatic Colorectal Cancer|
|Funding Request||In combination with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS|
|Pre Noc Submission||No|
|NOC Date||August 31, 2015|
|Manufacturer||Amgen Canada Inc.|
|Sponsor||Amgen Canada Inc.|
|Submission Date||September 8, 2017|
|Submission Deemed Complete||September 15, 2017|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||September 22, 2017|
|Check-point meeting||October 30, 2017|
|pERC Meeting||January 18, 2018|
|Initial Recommendation Issued||February 1, 2018|
|Feedback Deadline ‡||February 15, 2018|
|pERC Reconsideration Meeting||March 15, 2018|
|Final Recommendation Issued||March 29, 2018|
|Notification to Implement Issued||April 16, 2018|
|Therapeutic Area||Left Sided Metastatic Colorectal Cancer (mCRC)|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.